Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/19996
Título
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia
Autor(es)
Garcia-Delgado, Regina | de Miguel, Dunia | Bailen, Alicia | Ramon Gonzalez, Jose | Bargay Lleonart, Joan | Falantes, Jose F. | Andreu, Rafael | Fernando, Ramosh | Tormo, Mar | Brunet, Salut | Figueredo, M. A. | Casano, Javier | Medina, Angeles | Badiella, Llorenc | Fernandez Jurado, Antonio | Sanz, Guillermo | Asociacion Andaluza de Hematologia
Fecha de publicación
2014-07
Cita
Garcia-Delgado R, De Miguel D, Bailen A, Ramon Gonzalez J, Bargay Lleonart J, Falantes JF, et al. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Leuk Res. 2014 Jul;38(7):744-50. Epub 2014 Mar 19.
Idioma
Inglés
Tipo de documento
research article
Resumen
We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules.
Palabras clave
Acute myeloid leukemia | Azacitidine | Dosing schedules | Myelodysplastic syndromes | Overall survival | Safety
MESH
Antimetabolites, Antineoplastic | Aged, 80 and over | Aged | Adult | Leukemia, Myeloid, Acute | Azacitidine | Humans | Middle Aged | Male | Female | Proportional Hazards Models | Myelodysplastic Syndromes | Retrospective Studies
DECS
Modelos de Riesgos Proporcionales | Síndromes Mielodisplásicos | Femenino | Masculino | Azacitidina | Humanos | Persona de Mediana Edad | Anciano | Anciano de 80 o más Años | Antimetabolitos Antineoplásicos | Estudios Retrospectivos | Adulto | Leucemia Mieloide Aguda
Versión en línea
DOI
Aparece en las colecciones
Acceso a texto completo